Our study seems to confirm that dual therapy dolutegravir/ lamivudine is not associated with an increased risk of worsening inflammatory state in antiretroviral therapy–naive persons in comparison with standard triple regimens.
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir / Calza L, Bon I, Pensalfine G, Vitale S, Appolloni L, Viale P. - In: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. - ISSN 1525-4135. - ELETTRONICO. - 91:4(2022), pp. 9-11. [10.1097/QAI.0000000000003077]
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir
Calza L;Bon I;Viale P
2022
Abstract
Our study seems to confirm that dual therapy dolutegravir/ lamivudine is not associated with an increased risk of worsening inflammatory state in antiretroviral therapy–naive persons in comparison with standard triple regimens.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
